Douglas Roeder Biography and Net Worth

Director of Senseonics Holdings, Inc. Common Stock

Mr. Roeder was elected to our Board of Directors in December 2015. Mr. Roeder served on the Senseonics, Incorporated board of directors from October 2011 to December 2015. Mr. Roeder joined Delphi Ventures as an Associate in 1998, and has been a Partner of Delphi Ventures since 2000, focusing on medical devices, diagnostics and biotechnology. Prior to joining Delphi Ventures, Mr. Roeder was an Associate with Alex, Brown & Sons Healthcare Investment Banking Group. Mr. Roeder currently serves on the boards of directors of Tandem Diabetes, Inc. and several private companies. Mr. Roeder previously served on the board of directors of TriVascular Technologies, Inc. from 2008 to 2016. Mr. Roeder received his A.B. from Dartmouth College.

What is Douglas A. Roeder's net worth?: The estimated net worth of Douglas A. Roeder is at least $563.46 thousand as of November 7th, 2025. Mr. Roeder owns 99,727 shares of Senseonics Holdings, Inc. Common Stock stock worth more than $563,458 as of March 13th. This net worth evaluation does not reflect any other investments that Mr. Roeder may own. Learn More about Douglas A. Roeder's net worth.
How do I contact Douglas A. Roeder?: The corporate mailing address for Mr. Roeder and other Senseonics Holdings, Inc. Common Stock executives is 20451 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876. Senseonics Holdings, Inc. Common Stock can also be reached via phone at (301) 515-7260 and via email at [email protected]. Learn More on Douglas A. Roeder's contact information.
Has Douglas A. Roeder been buying or selling shares of Senseonics Holdings, Inc. Common Stock?: Douglas A. Roeder has not been actively trading shares of Senseonics Holdings, Inc. Common Stock during the past quarter. Most recently, on Friday, November 7th, Douglas A. Roeder bought 15,000 shares of Senseonics Holdings, Inc. Common Stock stock. The stock was acquired at an average cost of $5.83 per share, with a total value of $87,450.00. Following the completion of the transaction, the director now directly owns 99,727 shares of the company's stock, valued at $581,408.41. Learn More on Douglas A. Roeder's trading history.
Who are Senseonics Holdings, Inc. Common Stock's active insiders?: Senseonics Holdings, Inc. Common Stock's insider roster includes Timothy Goodnow (CEO), Sharon Larkin (Director), Douglas Roeder (Director), and Frederick Sullivan (CFO). Learn More on Senseonics Holdings, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Senseonics Holdings, Inc. Common Stock?: In the last twelve months, Senseonics Holdings, Inc. Common Stock insiders bought shares 3 times. They purchased a total of 30,415 shares worth more than $184,790.20. The most recent insider tranaction occured on November, 10th when Director Edelman Steven bought 10,000 shares worth more than $65,500.00. Insiders at Senseonics Holdings, Inc. Common Stock own 3.6% of the company. Learn More about insider trades at Senseonics Holdings, Inc. Common Stock.
Information on this page was last updated on 11/10/2025.

Douglas A. Roeder Insider Trading History at Senseonics Holdings, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/7/2025	Buy	15,000	$5.83	$87,450.00	99,727
8/30/2023	Buy	15,000	$10.80	$162,000.00	40,399
8/25/2021	Sell	10,787	$70.00	$755,090.00
5/19/2021	Sell	32	$41.60	$1,331.20
4/12/2021	Sell	247,695	$42.40	$10,502,268.00
4/9/2021	Sell	244,619	$47.80	$11,692,788.20
6/15/2018	Sell	49,019	$80.40	$3,941,127.60
6/12/2018	Sell	25,980	$77.40	$2,010,852.00

Douglas A. Roeder Buying and Selling Activity at Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc. Common Stock Company Overview

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Today's Range

Now: $5.64

$5.58

$5.93

50 Day Range

MA: N/A

2 Week Range

Now: $5.64

$5.25

$15.74

Volume

455,894 shs

Average Volume

504,173 shs

Market Capitalization

$235.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9